Pharmaceutically acceptable salts of eliglustat and their crystalline forms

Stable crystalline forms of eliglustat salts like naphthalene disulfonate and galactarate address formulation challenges, enhancing stability and reducing cardiac side effects by maintaining gradual plasma drug concentration.

JP2024542427AInactive Publication Date: 2024-11-15SPEROGENIX (SHANGHAI) MEDTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527575
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-11
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing eliglustat formulations face challenges in stability and hygroscopicity, leading to increased drug exposure and potential cardiac side effects, with existing salts being difficult to formulate in crystalline forms.

Method used

Development of pharmaceutically acceptable salts and crystalline forms of eliglustat, such as naphthalene disulfonate, galactarate, glutarate, and oxalate, which are stable, less hygroscopic, and have controlled solubility, reducing side effects by maintaining gradual plasma drug concentration.

Benefits of technology

The new crystalline forms of eliglustat salts provide improved stability and reduced hygroscopicity, minimizing cardiac side effects and enabling safer, more effective oral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542427000025
    Figure 2024542427000025
  • Figure 2024542427000026
    Figure 2024542427000026
  • Figure 2024542427000027
    Figure 2024542427000027
Patent Text Reader

Abstract

The present invention provides various pharma- ceutically acceptable salts of eliglustat, including naphthalenedisulfonate, oxalate, glutarate, galactarate, and various crystalline forms thereof, as well as pharmaceutical compositions comprising these salts and crystalline forms, processes for their preparation, and their use in the treatment of Gaucher disease, Fabry disease, and polycystic nephropathy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharma- ceutically acceptable salt of eliglustat and its crystalline form, a preparation method thereof, and a pharmaceutical composition containing said crystalline form and its use, which belong to the field of pharmaceutical technology. [Background technology]

[0002] Eliglustat, chemically known as N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinomethyl)ethyl]octanamide, is a potent, highly specific ceramide analogue inhibitor that reduces the production of glucosylceramide by targeting glucosylceramide synthase. Eliglustat capsules (Cerdelga®) were approved by the US FDA in 2014 for first-line long-term treatment of adult patients with type 1 Gaucher disease. Clinical studies have shown that coadministration of eliglustat capsules (Cerdelga capsules) with CYP2D6 and CYP3A4 inhibitors may significantly increase drug exposure, prolong PR, QTc and / or QRS heart beat intervals, and potentially cause arrhythmias. Pharmacokinetic / pharmacodynamic models predict that at plasma concentrations of eliglustat reaching 500 ng / mL, the interphases of PR, QRS, and QTcF will increase by a mean of 22 (26), 7 (10), and 13 (19) milliseconds. For extensive and intermediate metabolizers of CYP2D6, the dose is 84 mg twice daily, whereas for poor metabolizers of CYP2D6, the dose of eliglustat capsules is reduced to 84 mg once daily to prevent arrhythmia side effects in poor metabolizers of CYP2D6. Due to the above factors, the currently available eliglustat capsules (Cerdelga capsules) Cerdelga® have many inconveniences in clinical use.

[0003] US6916802B2 describes eliglustat and its preparation method, and briefly describes "pharmaceutical acceptable salts", such as inorganic acids such as sulfuric acid, hydrochloric acid, phosphoric acid, or organic acids such as acetate, etc. However, the physicochemical properties of the pharmaceutical acceptable salts are not studied, nor are the crystalline forms of the salts studied.

[0004] Although US7196205B2 briefly describes types of physiologically acceptable salts of eliglustat, the physicochemical properties of the pharma- ceutically acceptable salts are not studied, and the crystalline forms of the salts are not studied.

[0005] Due to the nature of eliglustat free base itself, it is technically difficult to obtain a stable solid salt form and crystalline form. For example, WO2011066325A1 describes that eliglustat salts include citrate, malate, fumarate, methanesulfonate and acetate, but these salts cannot be obtained in solid form. Although hydrochloride and 1:1 tartrate can be obtained in solid form, neither of them are crystalline forms and are too hygroscopic for formulation. Eliglustat hemi-tartrate can be prepared and synthesized more easily than the free base and other salts. The patent specifically discloses that eliglustat hemi-tartrate and its crystalline forms are crystalline, non-hygroscopic, water-soluble, and have better flow properties than the corresponding free base and other salts, making them suitable for large-scale production, and have major X-ray powder diffraction peaks at 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7° 2Θ angles. CN107445938A describes another L-hemi-tartrate crystalline form of eliglustat, whose X-ray powder diffraction shows major characteristic peaks at 10.2°, 12.4°, 13.6°, 14.9°, 20.1°, and 22.1° 2Θ angles, and whose DSC pattern shows an endothermic peak at 161°C-162°C.

[0006] The present invention provides a new eliglustat salt and its crystalline form that can exist in a stable solid form. Compared with the crystalline form A of eliglustat hemi-tartrate, eliglustat 1,5-naphthalenedisulfonate and its crystalline form have lower hygroscopicity and smaller difference in solubility in water and simulated gastric juice, so that the plasma drug concentration after oral administration is more gradual, and it is expected to reduce the side effect of arrhythmia caused by increased drug exposure. Summary of the Invention [Means for solving the problem]

[0007] The present invention provides pharma- ceutically acceptable salts, solvates and crystalline forms thereof of eliglustat, which may exist in a stable solid form.

[0008] In some embodiments, the solubility of the pharma- ceutically acceptable salts, solvates and / or crystalline forms of eliglustat in water and simulated gastric fluid is 6.0 mg / mL or less.

[0009] In some embodiments, the pharma- ceutically acceptable salt of eliglustat is a naphthalenedisulfonate, a galactarate, or a glutarate.

[0010] In some embodiments, the naphthalenedisulfonate salt of eliglustat can be selected from 1,5-naphthalenedisulfonate, 1,6-naphthalenedisulfonic acid, 1,7-naphthalenedisulfonic acid, 2,6-naphthalenedisulfonate, or 2,7-naphthalenedisulfonate.

[0011] In some embodiments, the molar ratio of 1,5-naphthalenedisulfonic acid of eliglustat to eliglustat is 1:1 or 1:2.

[0012] In some embodiments, the pharma- ceutically acceptable salt of eliglustat is a hydrate or non-solvate of 1,5-naphthalenedisulfonic acid salt. Hydrates of 1,5-naphthalenedisulfonic acid salt are hemihydrate, monohydrate, and dihydrate.

[0013] In some embodiments, crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat is provided, which has X-ray powder diffraction peaks at 2Θ angles of 4.9°, 5.9°, and 18.7° (±0.2°). Crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 7.0°, 10.4°, and 24.7° (±0.2°). Crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 14.2° and 16.2° (±0.2°). Crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 3A.

[0014] In some embodiments, crystalline form B of eliglustat 1,5-naphthalenedisulfonate is provided, which has X-ray powder diffraction peaks at 2Θ angles of 7.3°, 14.6°, and 6.5° (±0.2°). Crystalline form B of eliglustat 1,5-naphthalenedisulfonate further has X-ray powder diffraction peaks at 2Θ angles of 22.8°, 21.0°, and 20.8° (±0.2°). Crystalline form B of eliglustat 1,5-naphthalenedisulfonate further has X-ray powder diffraction peaks at 2Θ angles of 13.1°, 3.3°, and 15.1° (±0.2°). Crystalline form B of eliglustat 1,5-naphthalenedisulfonate has an X-ray powder diffraction pattern substantially similar to FIG. 4A.

[0015] In some embodiments, crystalline form C of eliglustat 1,5-naphthalenedisulfonate is provided, which has X-ray powder diffraction peaks at 2Θ angles of 9.4°, 13.6°, 20.1°, and 12.1° (±0.2°). Crystalline form C of eliglustat 1,5-naphthalenedisulfonate further has X-ray powder diffraction peaks at 2Θ angles of 24.3°, 12.8°, and 19.6° (±0.2°). Crystalline form C of eliglustat 1,5-naphthalenedisulfonate further has X-ray powder diffraction peaks at 2Θ angles of 6.2° and 14.0° (±0.2°). Crystalline form C of eliglustat 1,5-naphthalenedisulfonate has an X-ray powder diffraction pattern substantially similar to FIG. 5A.

[0016] In some embodiments, crystalline form A of eliglustat oxalate is provided, which has X-ray powder diffraction peaks at 2Θ angles of 7.5°, 15.5°, and 19.0° (±0.2°). The crystalline form A of eliglustat oxalate further has X-ray powder diffraction peaks at 2Θ angles of 10.0°, 22.3°, and 23.3° (±0.2°). Among the pharma- ceutically acceptable salts of eliglustat, the crystalline form A of eliglustat oxalate further has X-ray powder diffraction peaks at 2Θ angles of 12.8°, 18.3°, and 20.70° (±0.2°). In some embodiments, the crystalline form A of eliglustat oxalate has an X-ray powder diffraction pattern substantially similar to FIG. 6A.

[0017] In some embodiments, crystalline form A of eliglustat glutarate is provided, which has X-ray powder diffraction peaks at 2Θ angles of 5.1°, 19.3°, and 21.3° (±0.2°). Crystalline form A of eliglustat glutarate further has X-ray powder diffraction peaks at 2Θ angles of 15.5°, 6.4°, and 10.6° (±0.2°). Crystalline form A of eliglustat glutarate further has X-ray powder diffraction peaks at 2Θ angles of 18.6°, 21.9°, and 13.1° (±0.2°). In some embodiments, crystalline form A of eliglustat glutarate has an X-ray powder diffraction pattern substantially similar to FIG. 7A.

[0018] In some embodiments, crystalline form A of eliglustat galactarate is provided having X-ray powder diffraction peaks at 2Θ angles of 6.4°, 8.4°, and 20.7° (±0.2°). Crystalline form A of eliglustat galactarate further has X-ray powder diffraction peaks at 2Θ angles of 5.3°, 14.0°, and 12.4° (±0.2°). Crystalline form A of eliglustat galactarate further has X-ray powder diffraction peaks at 2Θ angles of 17.0°, 19.6°, and 17.9°±0.2° (±0.2°). In some embodiments, crystalline form A of eliglustat galactarate has an X-ray powder diffraction pattern substantially similar to FIG. 8A.

[0019] In some embodiments, the compound in the pharma- ceutically acceptable salt of eliglustat of the present invention is at least 60% by weight in the monocrystalline form, at least 70% by weight in the monocrystalline form, at least 80% by weight in the monocrystalline form, at least 90% by weight in the monocrystalline form, at least 95% by weight in the monocrystalline form, or at least 99% by weight in the monocrystalline form.

[0020] The present invention further provides a pharmaceutical composition, the active ingredient of which includes a pharma- ceutical acceptable salt of eliglustat, eliglustat 1,5-naphthalenedisulfonate hydrate, eliglustat 1,5-naphthalenedisulfonate crystalline form D, eliglustat 1,5-naphthalenedisulfonate crystalline form B, eliglustat 1,5-naphthalenedisulfonate crystalline form C, eliglustat oxalate crystalline form A, eliglustat glutarate crystalline form A, or eliglustat galactarate crystalline form A, and a pharma-ceutically acceptable carrier.

[0021] The compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, mucosally, or in ophthalmic formulations. As used herein, the term "parenterally" includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. In some aspects, the pharmaceutical compositions provided herein are administered orally in any orally acceptable dosage form, including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions.

[0022] A pharma- ceutically acceptable carrier refers to a non-toxic carrier, excipient, or vehicle that does not adversely affect the pharmacological activity of the compound with which it is formulated and that is safe for use in humans.

[0023] In certain embodiments, the pharmaceutical compositions provided herein include one or more selected from diluents, disintegrants, binders, surfactants, glidants, and lubricants.

[0024] The present invention further provides a method for preparing crystalline form D of eliglustat 1,5-naphthalenedisulfonate. In some embodiments, the method includes the steps of dissolving eliglustat free base and 1-1.1 equivalents of 1,5-naphthalenedisulfonic acid in methyl tert-butyl ether, magnetically stirring the mixture at room temperature, followed by centrifugation, and drying the resulting solid under vacuum at room temperature overnight to obtain crystalline form D of eliglustat 1,5-naphthalenedisulfonate.

[0025] In some embodiments, the method for preparing the crystalline form D of eliglustat 1,5-naphthalenedisulfonic acid salt comprises dissolving eliglustat free base and 1-1.1 equivalents of 1,5-naphthalenedisulfonic acid in methyl tert-butyl ether, magnetically stirring the mixture at room temperature for 1-3 days, centrifuging the mixture, and vacuum drying the solid at room temperature overnight. The 1,5-naphthalenedisulfonic acid may be a non-solvate or a hydrate, and specifically, 1,5-naphthalenedisulfonic acid tetrahydrate is selected.

[0026] The present invention further provides a method for preparing crystalline form B of eliglustat 1,5-naphthalenedisulfonate. In some embodiments, the method comprises the steps of dissolving eliglustat free base and 0.5 equivalents of 1,5-naphthalenedisulfonic acid in tetrahydrofuran / n-heptane, continuously suspending and stirring the mixture, and drying the precipitated solid to obtain crystalline form B of eliglustat 1,5-naphthalenedisulfonate.

[0027] In some embodiments, the method for preparing crystalline form B of eliglustat 1,5-naphthalenedisulfonate comprises the steps of dissolving eliglustat free base and 0.5 equivalents of 1,5-naphthalenedisulfonic acid in tetrahydrofuran / n-heptane (1:9, v:v), continuously suspending and stirring the mixture at a temperature of 20 to 40° C., and drying the precipitated solid to obtain crystalline form B of eliglustat 1,5-naphthalenedisulfonate.

[0028] The present invention provides a method for preparing crystalline form C of eliglustat 1,5-naphthalenedisulfonic acid. In some embodiments, the method includes the steps of: adding crystalline form B of 1,5-naphthalenedisulfonic acid to HO, stirring at room temperature to separate the solid, and drying with calcium oxide to obtain crystalline form C of eliglustat 1,5-naphthalenedisulfonic acid.

[0029] In some embodiments, the method for preparing crystalline form C of eliglustat 1,5-naphthalenedisulfonate comprises adding crystalline form B of 1,5-naphthalenedisulfonate to 10 times its weight of HO, stirring overnight at room temperature to isolate the solid, and drying in an oven containing calcium oxide for 24 hours to obtain crystalline form C of eliglustat 1,5-naphthalenedisulfonate.

[0030] The present invention further provides a method for preparing eliglustat oxalate crystalline form A. In some embodiments, the method includes the steps of dissolving eliglustat free base and 0.5 equivalents of oxalic acid in methyl tert-butyl ether, continuously suspending and stirring at 15 to 50° C., and drying the precipitated solid to obtain eliglustat 1,5-naphthalenedisulfonate oxalate crystalline form A.

[0031] In some embodiments, the method for preparing eliglustat oxalate crystalline form A includes the steps of dissolving eliglustat free base in methyl tert-butyl ether, adding 0.5 equivalents of oxalic acid in several portions while stirring, suspending and stirring at 40°C, reacting overnight, and then suction filtering the solid, separating it, and drying it under vacuum at room temperature to obtain eliglustat 1,5-naphthalenedisulfonate oxalate crystalline form A.

[0032] The present invention further provides a method for preparing eliglustat glutarate crystalline form A. In some embodiments, the method comprises the steps of dissolving eliglustat free base and 0.5 equivalents of glutaric acid in isopropyl acetate / n-heptane (1:5, v:v), continuously suspending and stirring the mixture at a temperature of 20 to 40° C., and drying the precipitated solid to obtain eliglustat glutarate crystalline form A.

[0033] In some embodiments, the method for preparing eliglustat glutarate crystalline form A includes the steps of dissolving eliglustat free base and 0.5 equivalents of glutaric acid in isopropyl acetate / n-heptane (1:5, v:v), suspending and stirring at room temperature for 1 day, and suspending and stirring at 40° C. for 2 days, and drying the precipitated solid to obtain eliglustat glutarate crystalline form A.

[0034] The present invention further provides a method for preparing eliglustat galactarate crystalline form A. In some embodiments, the method comprises the steps of dissolving eliglustat free base and 0.5 equivalents of galactaric acid in acetone / n-heptane (1:9, v:v), continuously suspending and stirring the mixture at a temperature of 35 to 45° C., and drying the precipitated solid to obtain eliglustat galactarate crystalline form A.

[0035] In some embodiments, the method for preparing eliglustat galactarate crystalline form A includes dispersing eliglustat free base in acetone / n-heptane (1:9, v:v), adding 0.5 equivalents of galactaric acid in several portions with stirring, and circulating the mixture at a temperature of 50°C to 5°C for 2 to 4 times, separating the solid, washing it with n-heptane, and drying it under vacuum at room temperature to obtain eliglustat galactarate crystalline form A.

[0036] The present invention further provides uses of pharma- ceutically acceptable salts of eliglustat, eliglustat 1,5-naphthalenedisulfonate hydrate, eliglustat 1,5-naphthalenedisulfonate crystalline form D, eliglustat 1,5-naphthalenedisulfonate crystalline form B, eliglustat 1,5-naphthalenedisulfonate crystalline form C, eliglustat oxalate crystalline form A, eliglustat glutarate crystalline form A, eliglustat galactarate crystalline form A in the treatment of Gaucher disease, Fabry disease and polycystic nephropathy.

[0037] The present invention further provides the use of a pharma- ceutically acceptable salt of eliglustat, eliglustat 1,5-naphthalenedisulfonate hydrate, eliglustat 1,5-naphthalenedisulfonate crystalline form D, eliglustat 1,5-naphthalenedisulfonate crystalline form B, eliglustat 1,5-naphthalenedisulfonate crystalline form C, eliglustat oxalate crystalline form A, eliglustat glutarate crystalline form A, eliglustat galactarate crystalline form A in the preparation of a medicament for treating Gaucher disease, Fabry disease, and polycystic nephropathy.

[0038] In some embodiments, the affected patient is an extensive, intermediate or poor metabolizer of CYP2D6.

[0039] In some embodiments, the Gaucher disease is type 1 Gaucher disease and the polycystic nephropathy is autosomal dominant polycystic nephropathy.

[0040] definition When used alone, when describing a pharma- ceutically acceptable salt of eliglustat, the terms "Form A", "Form B", and "Form C" refer to crystalline forms A, B, and C, respectively, of a pharma- ceutically acceptable salt of eliglustat. In this document, "Form A" and "crystalline form A", "Form B" and "crystalline form B", and "Form C" and "crystalline form C" may be used interchangeably.

[0041] "Crystalline" as used herein refers to a solid form of eliglustat or a pharma- ceutically acceptable salt thereof in which there is long-range order in the arrangement of atoms. The crystalline nature of a solid can be confirmed, for example, by examining the X-ray powder diffraction pattern. The compound is crystalline if the XRPD shows sharp peaks of intensity in the XRPD. "Crystalline" refers to a fully crystalline or partially crystalline solid, and includes solids that are at least 80%, 85%, 90%, 95% crystalline, and 99% crystalline by weight.

[0042] The term "solvate" refers to the incorporation of a stoichiometric or non-stoichiometric solvent or solvent mixture into a crystal structure.

[0043] The term "hydrate" refers to the incorporation of stoichiometric or non-stoichiometric water into the crystal structure. A hydrate is a solvate in which the solvent bound in the crystal structure is water. The term "anhydrous" when used in reference to a compound refers to essentially no solvent bound in the crystal structure, e.g., less than 0.1% by weight as determined by TGA, Karl Fischer analysis, or single crystal data. Anhydrous compounds are referred to herein as "anhydrous."

[0044] The term "major peak" refers to the three most intense peaks in an XRPD data pattern, or a peak having at least 50% of 100% relative intensity of the most intense peak.

[0045] The specific °2Θ values ​​in the XRPD listings of each crystalline form herein are reserved to the fourth decimal place, and any reserved values ​​to the first, second, third or fourth decimal places are deemed to be specific data disclosed herein and are incorporated by reference in the disclosure of this application. The 2-Θ values ​​of the X-ray powder diffraction patterns of the crystalline forms described herein may vary slightly due to differences in instruments and are also determined by differences in sample preparation and batch-to-batch variations. Therefore, unless otherwise defined, the XRPD patterns and / or 2-Θ peak values ​​described herein should not be construed as absolute and may vary by ±0.2 degrees. The 2-Θ values ​​provided herein were obtained using CuKα1 radiation.

[0046] Temperature values ​​(e.g., DSC peak temperature and DSC onset temperature) may vary slightly from instrument to instrument and are also determined by variations in sample preparation, rate of temperature increase during the course of an experiment, batch-to-batch variations in materials, and other environmental factors. Thus, unless otherwise defined, temperature values ​​given herein should not be construed as absolute and may vary by ±5°.

[0047] "Substantially identical XRPD patterns" or "substantially similar X-ray powder diffraction patterns" refers to the presence of at least 90% of the peaks indicated for ease of comparison purposes. It should be further understood that for ease of comparison purposes, some variation, e.g., ±0.2 degrees, is permitted between the positions of the 2-Θ peak values ​​and the positions indicated. When "X-ray powder diffraction peaks characterized in 2-Θ angles (±0.2°)" is followed by a list of 2-Θ peak positions of ±0.2°, it should be understood that this applies to each peak position listed. [Brief description of the drawings]

[0048] [Figure 1A] FIG. 1A is an XRPD pattern of eliglustat tartrate crystalline form A. [Figure 1B] FIG. 1B is the TGA / DSC curve of eliglustat tartrate crystalline form A. [Figure 1C] FIG. 1C is the 1H HMR pattern of eliglustat tartrate crystalline form A. [Figure 2A] FIG. 2A is an XRPD pattern of eliglustat free base crystalline form A. [Figure 2B] FIG. 2B is the TGA / DSC curve of eliglustat free base crystalline form A. [Figure 2C] FIG. 2C is the TGA / DSC curve of eliglustat free base crystalline form A. [Figure 3A] FIG. 3A is an XRPD pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form D. [Figure 3B] FIG. 3B is the TGA / DSC curve of eliglustat 1,5-naphthalenedisulfonate crystalline form D. [Figure 3C] FIG. 3C is the 1H HMR pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form D. [Figure 4A] FIG. 4A is an XRPD pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form B. [Figure 4B]FIG. 4B is the TGA / DSC curve of eliglustat 1,5-naphthalenedisulfonate crystalline form B. [Figure 4C] FIG. 4C is the 1H HMR pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form B. [Figure 5A] FIG. 5A is an XRPD pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form C. [Figure 5B] FIG. 5B is a TGA / DSC curve of eliglustat 1,5-naphthalenedisulfonate crystalline form C. [Figure 5C] FIG. 5C is the 1H HMR pattern of eliglustat 1,5-naphthalenedisulfonate crystalline form C. [Figure 6A] FIG. 6A is an XRPD pattern of eliglustat oxalate crystalline form A. [Figure 6B] FIG. 6B is the TGA / DSC curve of eliglustat oxalate crystalline form A. [Figure 6C] FIG. 6C is an XRPD pattern of eliglustat oxalate crystalline form A. [Figure 7A] FIG. 7A is an XRPD pattern of eliglustat glutarate crystalline form A. [Figure 7B] FIG. 7B is the TGA / DSC curve of eliglustat glutarate crystalline form A. [Figure 7C] FIG. 7C is the 1H HMR pattern of eliglustat glutarate crystalline form A. [Figure 8A] FIG. 8A is an XRPD pattern of eliglustat galactarate crystalline form A. [Figure 8B] FIG. 8B is the TGA / DSC curve of eliglustat galactarate crystalline form A. [Figure 8C] FIG. 8C is the 1H HMR pattern of eliglustat galactarate crystalline form A. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0049] As described in the Examples below, crystalline and amorphous forms are prepared according to the following general procedures. Typical solvent abbreviations used in this invention are outlined below. [Table 1]

[0050] solution Preparation of simulated gastric fluid (SGF) Weigh out 0.2 g of sodium chloride and 0.1 g of Triton X-100 into a 100 mL measuring flask, add pure water to dissolve, and stir until the solids are completely dissolved. Then add approximately 1.632 mL of hydrochloric acid (1 M), adjust the pH to 1.8 with 1 M hydrochloric acid or 1 M sodium hydroxide, and finally bring to volume with pure water.

[0051] Preparation of simulated fasting state intestinal fluid (FaSSIF) Weigh out 0.34 g of sodium dihydrogen phosphate (NaH2PO4, anhydrous), 0.042 g of sodium hydroxide, and 0.62 g of sodium chloride into a 100 mL measuring flask, add approximately 48 mL of pure water to dissolve, adjust the pH to 6.5 using 1 M hydrochloric acid or 1 M sodium hydroxide, and add pure water to the final volume to obtain a storage solution. Add 0.11 g of SIF powder to a 50 mL measuring flask, dissolve using the above storage solution to the final volume, and use ultrasonic waves to completely dissolve the powder.

[0052] XRPD The XRPD patterns were collected by a PANalytacal X-ray powder diffraction analyzer, and the XRPD parameters are listed in Table 2. [Table 2]

[0053] TGA and DSC TGA and DSC patterns are from a TA Q5000 / Discovery 5500 thermogravimetric analyzer and a TA Q2000 / Discovery 2500, respectively.

[0054] The samples were collected using a differential scanning calorimeter. The detailed parameters are shown in Table 3. [Table 3]

[0055] Dynamic Moisture Sorption DVS Dynamic moisture sorption (DVS) curves were collected on a Surface Measurement Systems (SMS) DVS Intrinsic. The relative humidity at 25°C was corrected for the deliquescence points of LiCl, MG(NO3)2, and KCl. Table 4 lists the DVS test parameters. [Table 4]

[0056] Solution NMR Liquid magnetic patterns were collected on a Bruker 400M nuclear magnetic resonance instrument using DMSO-d6 as the solvent.

[0057] Ion Chromatography / High Performance Liquid Chromatography (IC / HPLC) The purity test, dynamic solubility and stability test in the test were performed by Agilent 1260 high performance liquid chromatograph, and the salt formation molar ratio test of ions was performed by ion chromatography. The analysis conditions are shown in Tables 5 and 6. [Table 5] [Table 6]

[0058] Example 1 Preparation and Characterization of Eliglustat Tartrate Crystalline Form A Commercially available eligluristat tartrate was obtained and its XRPD pattern was measured. The XRPD pattern of the eligluristat tartrate is shown in Figure 1A, which indicates that the sample is in a crystalline form, and is consistent with the XRPD pattern data in Figure 1 of the specification drawing of WO2011066325A1, which is described as eligluristat tartrate crystal form A in the present invention. The TGA / DSC result (Figure 1B) shows that the sample has a weight loss of 0.2% when heated to 150°C, and an endothermic peak was observed at 165.9°C (peak value temperature). 1 H NMR was measured in DMSO-d6, and the results are shown in Figure 1C. The results showed that the molar ratio of tartaric acid to API was about 0.5, and no obvious organic solvent remained.

[0059] Example 2 Preparation and characterization of free eliglustat Free crystalline form A is prepared by the following method. Approximately 200 mg of starting tartrate salt crystalline form A is weighed into a beaker, 2 mL of deionized water is added to dissolve, 20 mL of saturated NaHCO3 solution is rapidly added to the solution, and the solution is stirred at room temperature for 1.5 hours. The resulting solid is collected by suction filtration, and dried overnight under vacuum at room temperature. The XRPD of the obtained sample is measured. Figure 2A shows that the sample exhibits a crystalline form, which is named as free crystalline form A, and its XRPD result is shown in Figure 2A. The TGA / DSC result (Figure 2B) shows that there is a weight loss of 0.8% when the sample is heated to 80°C, and a rapid heating peak is observed at 88.9°C (peak value temperature). 1 H NMR was measured in DMSO-d6, the results of which are shown in Figure 2C, and no obvious residual organic solvent was observed.

[0060] Example 3 Salt Form Screening Using the prepared free crystalline form A as raw material, 28 kinds of acidic ligands were selected, and a total of 154 salt form screening tests were set up in three stages. The specific steps of the screening test are as follows: Approximately 20 mg of the free crystalline form A sample and the corresponding ligand were weighed into an HPLC vial, and 0.5 mL of solvent was added and mixed to obtain a suspension. After suspension stirring at room temperature for 2 days (the third stage screening test was carried out at 40 ° C), the solid was centrifuged and dried in vacuum at room temperature. After stirring at room temperature, the obtained supernatant solution was stirred at 5 ° C or antisolvent (normal heptane) was added to induce solid precipitation, and if there is still supernatant, it was transferred to room temperature and opened to volatilize to obtain a solid. The obtained gel-like material was transferred to a temperature of 50 ° C ~ 5 ° C and circulated (1 cycle: increase the temperature to 50 ° C at 4.5 ° C / min, hold at 50 ° C for 2 hours, decrease the temperature to 5 ° C at 0.1 ° C / min, hold at 5 ° C for 2 hours). According to the XRPD results of the solids obtained by the test, a total of 11 salt forms were obtained through the three-stage XRPD screening test, including 1,5-naphthalenedisulfonate crystal form A or B, oxalate crystal form A, galactarate crystal form A, malate crystal form A or B, glutarate crystal form A, succinate crystal form A, phosphate crystal form A, hydrochloride crystal form A and fumarate crystal form A. The XRPD, TGA, DSC and 1 The results of characterization by 1 H NMR or IC / HPLC are summarized in Tables 7-1 to 7-4. [Table 7-1] [Table 7-2] [Table 8] [Table 9] [Table 10]

[0061] Crystal Form Screening Example 4 Preparation and Characterization of 1,5-Naphthalenedisulfonic Acid Crystalline Form D 49.6 mg of eglistat free base and 45.7 mg of 1,5-naphthalenedisulfonic acid tetrahydrate (1.1 equivalents) were dissolved in 2.0 mL of MTBE, and the mixture was magnetically stirred (about 750 rpm) at room temperature for about 3 days and then centrifuged (10,000 rpm, 2 minutes). The resulting solid was vacuum dried at room temperature overnight to obtain eglistat 1,5-naphthalenedisulfonic acid salt crystal form D.

[0062] The XRPD result of the sample is shown in Figure 3A. The TGA / DSC curve is shown in Figure 3B, and the results show that the weight loss is 9.82% when heated to 130°C, and endothermic signals are observed at 114.7 and 159.8°C (peak temperatures). 1 The 1 H NMR pattern was measured in DMSO-d6 and is listed in Figure 3C, and the results indicate that the molar ratio of ligand acid to API is approximately 1.0. [Table 11]

[0063] Example 5 Preparation and Characterization of 1,5-Naphthalenedisulfonic Acid Crystalline Form B The free crystalline form A and 0.5 equivalents of 1,5-naphthalenedisulfonic acid were suspended and stirred in THF / n-heptane (1:9, v:v) at room temperature for 1 day, then at 40°C for 2 days. The solid was centrifuged and dried in vacuum to obtain the free crystalline form A.

[0064] The XRPD result of the sample is shown in Figure 4A. The TGA / DSC curve is shown in Figure 4B, and the result shows that the weight loss is 1.5% when heated to 150°C, and endothermic signals are observed at 75.9 and 167.9°C (peak temperature). 1 The H NMR pattern was measured in DMSO-d6 and is listed in Figure 4C, and the results show that the molar ratio of ligand acid to API was approximately 0.5 and no residual solvent was observed. [Table 12]

[0065] Example 6 Preparation and Characterization of 1,5-Naphthalenedisulfonic Acid Crystalline Form C A sample of 119.9 mg of 1,5-naphthalenedisulfonic acid salt crystalline form B was weighed into a 3-mL glass bottle, added with 2 mL of H20, magnetically stirred (~750 rpm) at room temperature overnight, centrifuged the solid, and dried in an oven containing calcium oxide for 24 hours, after which the solid was collected for characterization testing and study.

[0066] The XRPD results are shown in Figure 5A. The TGA and DSC results are listed in Figure 5B. The TGA results showed that there was a 6.6% weight loss when heated from room temperature to 150°C, and the DSC curve showed endothermic peaks at 73.5 and 171.4°C (peak temperature). 1 H NMR was measured in DMSO-d6, and the results are listed in Figure 5C. The molar ratio of the ligand acid to API in the sample was 0.5, and no obvious residual THF or n-heptane was detected. Through heating test, 1,5-naphthalenedisulfonic acid crystal form C was identified. When 1,5-naphthalenedisulfonic acid crystal form C was heated to 100°C under nitrogen protection and cooled to room temperature, it turned into 1,5-naphthalenedisulfonic acid crystal form B. Combining the weight loss of the TGA curve, the liquid nuclear magnetic results and the heating test results, 1,5-naphthalenedisulfonic acid crystal form C is a dihydrate. [Table 13-1] [Table 13-2]

[0067] Example 7 Preparation and Characterization of Oxalate Crystalline Form A 300.4 mg of free crystalline form A sample was weighed into a 20-mL glass bottle and dissolved in 15 mL of MTBE. 33.0 mg of oxalic acid (approximately 0.5 equivalents) was added in several portions under magnetic stirring (~750 rpm) and the mixture was stirred in suspension at 40°C. After reacting overnight, the solid was separated by suction filtration and dried under vacuum at room temperature to collect the solid for characterization testing and research.

[0068] The XRPD results are shown in Figure 6A. The TGA and DSC results are listed in Figure 6B. The TGA results showed that there was a 7.4% weight loss when heated from room temperature to 150°C, and the DSC curve showed endothermic peaks at 90.1 and 116.0°C (peak temperature). 1 H NMR was measured in DMSO-d6, and the results are shown in Figure 6C. No obvious MTBE residue was detected in the sample. The IC / HPLC test results show that the molar ratio of the ligand acid to the API in the sample is 0.5. [Table 14]

[0069] Example 8 Preparation and characterization of galactarate salt crystalline form A 500.8 mg of free crystalline form A sample was weighed into a 20-mL glass bottle and dispersed in 15 mL of acetone / n-heptane (1:9, v:v). 129.8 mg of galactaric acid (approximately 0.5 equivalents) was added in portions under magnetic stirring (~750 rpm) and reacted at 50°C. After overnight reaction, the solution on top was clear and the solid on the bottom was a viscous gel. The system was temperature cycled (50°C to 5°C) twice, and the reaction system turned into a white suspension. After overnight reaction, the solid was separated by suction filtration and washed with n-heptane, and vacuum dried at room temperature for 2 days, after which the solid was collected for characterization and study.

[0070] The XRPD test results are listed in Figure 8A. The TGA and DSC results are listed in Figure 8B. 1H NMR was measured in DMSO-d6, the results of which are listed in Figure 8C, and no obvious residual MTBE was detected in the sample. [Table 15]

[0071] Example 9 Preparation and characterization of malate crystal forms A / B Free crystalline form A and 0.5 equivalents of L-malic acid were suspended and stirred in EtOAc at room temperature for 1 day, and the solid was centrifuged and dried in vacuum to obtain malate crystalline form A. The sample was obviously deliquesced under room temperature conditions, so no other characterization data was collected.

[0072] Free crystalline form A and 0.5 equivalents of L-malic acid were suspended in IPAc / n-heptane (1:5, v:v) at room temperature for 1 day and at 40°C for 2 days, after which the solid was centrifuged and vacuum dried to obtain malate crystalline form B. The sample was not further characterized because it absorbed moisture strongly at room temperature.

[0073] Example 10 Preparation and Characterization of Glutarate Crystalline Form A Glutarate crystalline form A was obtained by suspending and stirring free crystalline form A and 0.5 equivalents of glutaric acid in IPAc / n-heptane (1:5, v:v) at room temperature for 1 day and at 40° C. for 2 days. The solid was centrifuged and dried in vacuum for further characterization.

[0074] The XRPD result of the sample is shown in Figure 7A. The TGA / DSC curve is shown in Figure 7B. The result shows that the weight loss is 3.7% when heated to 150°C, and endothermic signals are observed at 86.7, 101.4 and 177.4°C (peak temperature). From this result, it is inferred that it is a mixture of glutarate crystalline form A and free crystalline form A. 1 The H NMR pattern was measured in DMSO-d6 and is listed in Figure 7C, and the results show that the molar ratio of ligand acid to API was approximately 0.7 and no residual solvent was observed. [Table 16]

[0075] Example 11 Preparation and Characterization of Succinate Crystalline Form A The solid obtained after suspension stirring of free crystalline form A and 0.5 equivalents of succinic acid in IPAc / n-heptane (1:5, v:v) at room temperature for 1 day and at 40°C for 2 days is free crystalline form A. After adding an extra 0.25 equivalents of succinic acid, the mixture was further suspended and stirred at 40°C for 1 week, centrifuged, and the obtained solid was dried in vacuum and used for the subsequent characterization.

[0076] The XRPD results of the sample are shown in Table 14. The TGA / DSC curve shows that the weight loss when heated to 120°C is 7.3% and endothermic signals are observed at 83.7 and 169.9°C. 1 The H NMR pattern was measured in DMSO-d6 and the results show that the molar ratio of ligand acid to API was about 0.6 and no residual solvent was observed. [Table 17]

[0077] Example 12 Preparation and Characterization of Phosphate Crystalline Form A The free crystalline form A and 1 equivalent of phosphoric acid (85%) were suspended and stirred in MTBE at room temperature for 1 day, and the solid was centrifuged and dried in vacuum before being used for further characterization.

[0078] The XRPD results of the sample are shown in Table 15. TGA / DSC shows that the weight loss when heated to 100° C. was 4.4% and endothermic signals were observed at 79.7, 106.4 and 131.5° C. (peak temperatures). 1H NMR pattern was measured in DMSO-d6 and the results show that no residual solvent was observed. IC / HPLC test results show that the molar ratio of ligand acid to API in the sample is 1.4. [Table 18]

[0079] Example 13 Preparation and characterization of hydrochloride crystalline form A A gel was formed by adding n-heptane antisolvent to the supernatant obtained by suspending and stirring the free crystalline form A sample in EtOAc at room temperature. The gel sample was subjected to a temperature cycle from 50°C to 5°C, and the solid sample obtained after 2 days was centrifuged and vacuum dried for subsequent characterization.

[0080] The XRPD results of the sample are shown in Table 16. The TGA / DSC results show that the weight loss is 11.7% when heated to 150℃, and endothermic signals are observed at 48.6 and 93.0℃ (peak temperature). The amount of the sample obtained in the screening is insufficient, so the nuclear magnetic test is not performed. The IC / HPLC test results of the sample show that the molar ratio of the ligand acid to the API in the sample is 1.0. [Table 19]

[0081] Example 14 Preparation and Characterization of Fumarate Crystalline Form A A sample of free crystalline form A and 0.5 equivalents of fumaric acid were suspended and stirred in EtOH / n-heptane (1:1, v:v) at room temperature to obtain a supernatant solution, to which n-heptane antisolvent was added to obtain an oily substance, which was opened at room temperature to evaporate and the obtained solid was dried in vacuum for further characterization. The XRPD results of the sample are shown in Table 17. The TGA / DSC curve shows that the weight loss when heated to 100°C was 9.1%, and endothermic signals were observed at 54.6, 86.8, and 134.1°C (peak temperature). 1 The H NMR pattern was measured in DMSO-d6 and the results indicate that the molar ratio of ligand acid to API was about 0.5 and no residual solvent was observed. [Table 20]

[0082] Example 15 Dynamic Solubility Test The dynamic solubilities of 1,5-naphthalenedisulfonate crystalline form B / crystalline form C, oxalate crystalline form A, tartrate crystalline form A and free crystalline form A in water and three biological solvents were evaluated.

[0083] In the test, the solid input concentration was ~10mg / mL (~40mg solid input in 4mL solvent) and mixed by rotation at 37°C, and the solubility of each sample was measured in four systems, water, SGF, FaSSIF, and FeSSIF1, at different time points (1, 4, and 24 hours). After sampling at each time point, centrifugal filtration (0.45μm PTFE filter head) was performed to measure the free form concentration and pH value in the filtrate, and XRPD of the solid sample after centrifugation was measured. The results of the solubility test are summarized in Table 18. [Table 21]

[0084] Example 16 Hygroscopicity Evaluation Hygroscopicity evaluation was performed for 1,5-naphthalenedisulfonate crystal form B / crystal form C, oxalate crystal form A, tartrate crystal form A and free crystal form A using DVS.

[0085] The results showed that at 25°C and humidity higher than 80%RH, 1,5-naphthalenedisulfonate crystal B had obvious hygroscopic weight gain and changed to crystal form C after the DVS test. The hygroscopic weight gain of 1,5-naphthalenedisulfonate crystal form C at 25°C / 80%RH was 0.33wt%, and no change in crystal form was observed after the DVS test. The hygroscopic weight gain of oxalate crystal form A at 25°C / 80%RH was 7.64wt%, and when the humidity was lower than 10%RH, obvious weight loss was observed and no change in crystal form was observed after the DVS test. The tartrate crystal form A sample was slightly hygroscopic, with a hygroscopic weight gain of 1.11wt% at 25°C / 80%RH, and the free crystal form A sample had almost no hygroscopicity3, and both samples did not change in crystal form after the DVS test. The results of the DVS test are listed in Table 19. [Table 22]

[0086] Example 17 Solid State Stability Evaluation After 1,5-naphthalenedisulfonic acid crystal form C was left unopened for 1 week, 3 weeks and 4 weeks under conditions of 25℃ / 60%RH and 40℃ / 75%RH, the physical and chemical stability of the sample was examined by XRPD and HPLC, and the stability data of tartaric acid crystal form A and free crystal form A for 1 week, 2 weeks and 4 weeks were used as reference. At the same time, the stability of 1,5-naphthalenedisulfonic acid crystal form B and oxalic acid crystal form A was examined when left unopened for 1 week under conditions of 25℃ / 60%RH and 40℃ / 75%RH. As a result, it was found that there was no change in crystal form or decrease in HPLC purity when the samples of 1,5-naphthalenedisulfonic acid crystal form C, tartrate crystal form A and free crystal form A were left unopened for 4 weeks under the corresponding conditions. The samples of 1,5-naphthalenedisulfonate crystal form B and oxalate crystal form A did not show any decrease in HPLC purity even when left open for one week under the corresponding conditions. However, the sample of 1,5-naphthalenedisulfonate crystal form B partially changed to crystal form C when left open for one week under the conditions of 40°C / 75%RH.

[0087] Example 18: Efficacy Study Plasma levels of glucosylceramide (GL-1) are recognized as a biomarker for substrate synthesis therapy (SRT) in patients with Gaucher disease and as a surrogate biomarker for SRT in patients with Fabry disease, to assess the biological effects of the newly discovered salts in preclinical populations.

[0088] Although many embodiments have been described, the scope of the present disclosure is limited by the appended claims, not by the specific embodiments presented by way of example. The contents of all references cited in this application in their entirety (including literature references, published patents, published patent applications, and co-pending patent applications) are expressly incorporated herein by reference in their entirety. Unless otherwise defined, all scientific and technical terms used in this application have the meanings familiar to those skilled in the art.

Claims

1. A pharma- ceutically acceptable salt of eliglustat, characterized in that the solubility of said pharma-ceutically acceptable salt in water and simulated gastric fluid is 6.0 mg / mL or less.

2. A pharma- ceutically acceptable salt of eliglustat, characterized in that the pharma- ceutically acceptable salt is a naphthalenedisulfonate, a galactarate, or a glutarate.

3. A pharma- ceutically acceptable salt of eliglustat, characterized in that the naphthalenedisulfonic acid salt is a 1,5-naphthalenedisulfonic acid salt.

4. The pharma- ceutically acceptable salt of eliglustat according to claim 3, wherein the molar ratio of 1,5-naphthalenedisulfonic acid to eliglustat is 1:1 or 1:

2.

5. The pharma- ceutically acceptable salt of eliglustat according to claim 4, wherein the pharma- ceutically acceptable salt is a hydrate or a non-solvate of 1,5-naphthalenedisulfonic acid salt.

6. The pharma- ceutically acceptable salt of eliglustat according to claim 5, wherein the hydrate of 1,5-naphthalenedisulfonic acid salt is a hemihydrate, a monohydrate or a dihydrate.

7. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 6, wherein the salt is crystalline form D of 1,5-naphthalenedisulfonic acid salt and has X-ray powder diffraction peaks at 2Θ angles of 4.9°, 5.9°, and 18.7° (±0.2°).

8. 8. The pharma- ceutically acceptable salt of eliglustat according to claim 7, wherein the crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 7.0°, 10.4°, and 24.7° (±0.2°).

9. 9. The pharma- ceutically acceptable salt of eliglustat according to claim 8, wherein the crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 14.2° and 16.2° (±0.2°).

10. 8. The pharma- ceutically acceptable salt of eliglustat according to claim 7, wherein the crystalline form D of 1,5-naphthalenedisulfonic acid salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 3A.

11. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 6, wherein the salt is crystalline form B of 1,5-naphthalenedisulfonic acid salt and has X-ray powder diffraction peaks at 2Θ angles of 7.3°, 14.6°, and 6.5° (±0.2°).

12. 12. The pharma- ceutically acceptable salt of eliglustat according to claim 11, wherein the crystalline form B of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 22.8°, 21.0°, and 20.8° (±0.2°).

13. 13. The pharma- ceutically acceptable salt of eliglustat according to claim 12, wherein the crystalline form B of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 13.1°, 3.3°, and 15.1° (±0.2°).

14. 14. The pharma- ceutically acceptable salt of eliglustat according to claim 13, wherein the crystalline form B of 1,5-naphthalenedisulfonic acid salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 4A.

15. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 6, wherein the salt is crystalline form C of 1,5-naphthalenedisulfonic acid salt and has X-ray powder diffraction peaks at 2Θ angles of 9.4°, 13.6°, 20.1°, and 12.1° (±0.2°).

16. 16. The pharma- ceutically acceptable salt of eliglustat according to claim 15, wherein the crystalline form C of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 24.3°, 12.8°, and 19.6° (±0.2°).

17. 17. The pharma- ceutically acceptable salt of eliglustat according to claim 16, wherein the crystalline form C of 1,5-naphthalenedisulfonic acid salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 6.2° and 14.0° (±0.2°).

18. 16. The pharma- ceutically acceptable salt of eliglustat according to claim 15, wherein the crystalline form C of 1,5-naphthalenedisulfonic acid salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 5A.

19. A pharma- ceutically acceptable salt of eliglustat, said salt being in crystalline form A of the oxalate salt and having X-ray powder diffraction peaks at 2Θ angles of 7.5°, 15.5°, and 19.0° (±0.2°).

20. 20. The pharma- ceutically acceptable salt of eliglustat according to claim 19, wherein the crystalline form A of the oxalate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 10.0°, 22.3°, and 23.3° (±0.2°).

21. 21. The pharma- ceutically acceptable salt of eliglustat according to claim 20, wherein the crystalline form A of the oxalate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 12.8°, 18.3°, and 20.70° (±0.2°).

22. 20. The pharma- ceutically acceptable salt of eliglustat according to claim 19, wherein the crystalline form A of the oxalate salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 6A.

23. 3. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 2, wherein the salt is crystalline form A of the glutarate salt and has X-ray powder diffraction peaks at 2Θ angles of 5.1°, 19.3°, and 21.3° (±0.2°).

24. 24. The pharma- ceutically acceptable salt of eliglustat according to claim 23, wherein the crystalline form A of the glutarate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 15.5°, 6.4°, and 10.6° (±0.2°).

25. 25. The pharma- ceutically acceptable salt of eliglustat according to claim 24, wherein the crystalline form A of the glutarate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 18.6°, 21.9°, and 13.1° (±0.2°).

26. 24. The pharma- ceutically acceptable salt of eliglustat according to claim 23, wherein the crystalline form A of the glutarate salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 7A.

27. 3. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 2, wherein the salt is crystalline form A of the galactarate salt and has X-ray powder diffraction peaks at 2Θ angles of 6.4°, 8.4°, and 20.7° (±0.2°).

28. 28. The pharma- ceutically acceptable salt of eliglustat according to claim 27, wherein the crystalline form A of the galactarate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 5.3°, 14.0°, and 12.4° (±0.2°).

29. 29. The pharma- ceutically acceptable salt of eliglustat according to claim 28, wherein the crystalline form A of the galactarate salt of eliglustat further has X-ray powder diffraction peaks at 2Θ angles of 17.0°, 19.6°, and 17.9° (±0.2°).

30. 28. The pharma- ceutically acceptable salt of eliglustat according to claim 27, wherein the crystalline form A of the galactarate salt of eliglustat has an X-ray powder diffraction pattern substantially similar to that shown in Figure 8A.

31. The pharma- ceutically acceptable salt of eliglustat according to any one of claims 7 to 30, wherein the compound is at least 60% by weight in the single crystalline form, at least 70% by weight in the single crystalline form, at least 80% by weight in the single crystalline form, at least 90% by weight in the single crystalline form, at least 95% by weight in the single crystalline form or at least 99% by weight in the single crystalline form.

32. 23. A pharmaceutical composition comprising a pharma- ceutical acceptable salt of eliglustat according to any one of claims 1 to 4, or a hydrate of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 5 to 6, or crystalline form D of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 7 to 10, or crystalline form B of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 11 to 14, or crystalline form C of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 15 to 18, or crystalline form A of the oxalate according to any one of claims 19 to 22, or crystalline form A of the glutarate according to any one of claims 23 to 26, or crystalline form A of the galactarate according to any one of claims 31 to 34, and a pharma-ceutical acceptable carrier.

33. A method for preparing crystalline form D of eliglustat 1,5-naphthalenedisulfonic acid, comprising dissolving eliglustat free base and 1-1.1 equivalents of 1,5-naphthalenedisulfonic acid in methyl tert-butyl ether, magnetically stirring the mixture at room temperature for 1-3 days, centrifuging the mixture, and vacuum drying the resulting solid at room temperature overnight.

34. A method for preparing crystalline form B of eliglustat 1,5-naphthalenedisulfonic acid salt, comprising dissolving eliglustat free base and 0.5 equivalents of 1,5-naphthalenedisulfonic acid in tetrahydrofuran / n-heptane (1:9, v:v), continuously suspending and stirring the mixture at a temperature of 20-40°C, and drying the precipitated solid.

35. The crystal form B of 1,5-naphthalenedisulfonic acid salt is 2 2. A method for preparing the crystalline form C of eliglustat 1,5-naphthalenedisulfonate, comprising adding the crystalline form C of eliglustat 1,5-naphthalenedisulfonate to 1,0,000 mol / L of 1 ...

36. A method for preparing eliglustat oxalate crystalline form A, comprising dissolving eliglustat free base and 0.5 equivalents of oxalic acid in methyl tert-butyl ether, continuously suspending and stirring the mixture at 15 to 50°C, and drying the precipitated solid.

37. A method for preparing eliglustat glutarate crystalline form A, comprising dissolving eliglustat free base and 0.5 equivalents of glutaric acid in isopropyl acetate / n-heptane (1:5, v:v), continuously suspending and stirring the mixture at a temperature of 20-40°C, and drying the precipitated solid.

38. A method for preparing crystalline form A of eliglustat galactarate, comprising dispersing eliglustat free base and 0.5 equivalents of galactaric acid in acetone / n-heptane (1:9, v:v), continuously suspending and stirring the mixture at a temperature of 35-45°C, and drying the precipitated solid.

39. Use of a pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 4, or a hydrate of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 5 to 6, or crystalline form D of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 7 to 10, or crystalline form B of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 11 to 14, or crystalline form C of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 15 to 18, or crystalline form A of the oxalate according to any one of claims 19 to 22, or crystalline form A of the glutarate according to any one of claims 23 to 26, or crystalline form A of the galactarate according to any one of claims 27 to 30, in the treatment of Gaucher disease, Fabry disease, and polycystic nephropathy.

40. 40. The use of claim 39, wherein the patient having the disease is an extensive metabolizer, an intermediate metabolizer or a poor metabolizer of CYP2D6.

41. 41. The use according to claim 39 or 40, wherein said Gaucher disease is type 1 Gaucher disease and said polycystic nephropathy is autosomal dominant polycystic nephropathy.

42. Use of a pharma- ceutically acceptable salt of eliglustat according to any one of claims 1 to 4, or a hydrate of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 5 to 6, or crystalline form D of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 7 to 10, or crystalline form B of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 11 to 14, or crystalline form C of eliglustat 1,5-naphthalenedisulfonate according to any one of claims 15 to 18, or crystalline form A of the oxalate salt according to any one of claims 19 to 22, or crystalline form A of the glutarate salt according to any one of claims 23 to 26, or crystalline form A of the galactarate salt according to any one of claims 27 to 30, in the preparation of a medicament for treating Gaucher disease, Fabry disease, or polycystic nephropathy.

43. 43. The use of claim 42, wherein the patient having the disease is an extensive metabolizer, an intermediate metabolizer or a poor metabolizer of CYP2D6.

44. 44. The use according to claim 42 or 43, wherein said Gaucher disease is type 1 Gaucher disease and said polycystic nephropathy is autosomal dominant polycystic nephropathy.